Comparison between Pre-operative Buccal and Rectal Misoprostol for Control of Blood Loss in Elective Cesarean Section: A Randomized Comparative Study.
Abstract
Background: Postpartum hemorrhage continues to be a major factor contributing to maternal mortality globally. Misoprostol, a synthetic prostaglandin E1 analogue, has emerged as an effective uterotonic agent, but the optimal route of pre-operative administration for blood loss control during elective cesarean section remains controversial. Methods: This interventional comparative study was conducted at Military Hospitals, Egypt, including 132 women undergoing elective lower segment cesarean section. Participants were randomly allocated into two equal groups: Group 1 (n=66) received 400 mcg misoprostol rectally, and Group 2 (n=66) received 400 mcg misoprostol buccally after induction of spinal anesthesia. All patients were given 20 IU of oxytocin after delivery. The main results measured were blood loss during and after the operation. Secondary outcomes consisted of changes in hemoglobin and hematocrit, the requirement for extra uterotonics, and adverse effects. Results: Rectal misoprostol was linked to notably reduced intraoperative blood loss (236.72±23.48 mL vs. 303.33±59.51 mL, p<0.0001) and postoperative blood loss (86.27±17.17 mL vs. 130.38±39.01 mL, p<0.0001) compared to buccal administration. Post-operative hemoglobin (10.88±0.52 vs. 10.47±0.30 g/dL, p<0.0001) and hematocrit (31.46±1.41% vs. 29.38±1.46%, p<0.0001) were significantly higher in the rectal group. The need for additional uterotonics was lower in the rectal group (24.24% vs. 51.51%, p=0.0012). Side effect profiles were comparable between groups. Conclusion: Pre-operative rectal misoprostol is more effective than buccal misoprostol in minimizing bleeding during and post elective cesarean delivery, with better preservation of post-operative hemoglobin and hematocrit levels and reduced need for additional uterotonics.
